Logo

American Heart Association

  31
  0


Final ID:

TAVR with Leaflet Modification: Worth the Trouble?

  • Dvir, Danny  ( SZMC , Jerusalem , Israel )
  • Khan, Jaffar  ( NHLBI , Bethesda , Maryland , United States )
  • Lederman, Robert  ( NHLBI , Bethesda , Maryland , United States )
  • Greenbaum, Adam  ( Emory , Atlanta , Georgia , United States )
  • Author Disclosures:
    Danny Dvir: No Answer | Jaffar Khan: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:Assigned to NIH on leaflet modification devices:Active (exists now) ; Individual Stocks/Stock Options:Cuspa Medical:Active (exists now) ; Individual Stocks/Stock Options:Transmural Systems:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) | Robert Lederman: DO NOT have relevant financial relationships | Adam Greenbaum: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Emboliner:Active (exists now) ; Consultant:Polares:Active (exists now) ; Individual Stocks/Stock Options:Excision Medical:Active (exists now) ; Individual Stocks/Stock Options:Transmural Systems:Active (exists now) ; Speaker:Abbott:Active (exists now) ; Consultant:Medtronic:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
Debate: CABG is Still a Reliable Option

Sandner Sigrid, Lawton Jennifer, Zwischenberger Brittany, Ruel Marc

Surgical Options Should Be Based on progression Rate and Type of TAVR Implanted

Fukuhara Shinichi, Yang Bo, Chen Edward, Sultan Ibrahim

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available